Qyuns Therapeutics Co., Ltd. Class H (2509) AI Stock Analysis

• Market Cap: HK$4.76B
• Dividend Yield: N/A
• Average Volume (3M): 509.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 339
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 227,071,600
• 10 Day Avg. Volume: 251,067
• 30 Day Avg. Volume: 509,817
• PEG Ratio: 0.12
• Price to Book (P/B): 6.64
• Price to Sales (P/S): 9.58
• P/FCF Ratio: -8.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$40.25
• Price Target Upside: 40.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: HK$22.00 ▼(-23.02% Downside)

The overall stock score of 46 reflects significant financial challenges, including negative profitability and cash flow issues, despite strong revenue growth. Technical indicators suggest mixed momentum, with potential overbought conditions. The valuation is unattractive due to a negative P/E ratio and no dividend yield.

Positive Factors

Revenue Growth

The substantial revenue growth indicates strong market demand and successful product adoption, which can support long-term business expansion and investment in R&D.

Gross Profit Margin Improvement

Improved gross profit margins suggest better cost management and operational efficiency, enhancing the company's ability to reinvest in growth initiatives.

Strategic Partnerships

Strategic partnerships provide access to additional resources, expertise, and markets, potentially accelerating product development and commercialization.

Negative Factors

High Leverage

High leverage can increase financial risk and limit flexibility, potentially impacting the company's ability to invest in growth or weather economic downturns.

Negative Profitability

Ongoing profitability challenges can hinder the company's ability to generate sustainable cash flows and fund future growth without external financing.

Negative Cash Flow

Negative cash flow indicates that the company is not generating enough cash from operations to cover its expenses, which may necessitate additional financing.

Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Qyuns Therapeutics Co., Ltd. Class H (2509) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases, particularly in the fields of oncology and autoimmune disorders. The company specializes in research, development, and commercialization of biopharmaceutical products, leveraging cutting-edge technology and scientific research to address unmet medical needs. Qyuns Therapeutics aims to provide novel treatment options through its pipeline of drug candidates, enhancing patient care and outcomes.

How the Company Makes Money

Qyuns Therapeutics generates revenue primarily through the sale of its biopharmaceutical products, which includes both proprietary drugs and those developed in collaboration with strategic partners. The company's revenue model includes direct sales of approved therapies, milestone payments from partnerships, and royalties from drug sales. Significant partnerships with larger pharmaceutical firms for co-development and licensing agreements also contribute to its earnings, as these collaborations can provide upfront payments and shared revenue from future sales. Additionally, Qyuns may receive funding through grants and research contracts, aiding in the advancement of its therapeutic pipeline.

Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview

Summary

Qyuns Therapeutics Co., Ltd. shows strong revenue growth, but profitability and cash flow remain significant challenges. The company faces high leverage and needs to improve operational efficiency and cash flow management to enhance financial stability.

Income Statement

The company has shown significant revenue growth from 2023 to 2024, with a growth rate of 976.54%. However, the net profit margin remains negative due to substantial net losses, indicating ongoing profitability challenges. The gross profit margin improved to 58.05% in 2024, suggesting better cost management. Despite these improvements, the EBIT and EBITDA margins are still negative, reflecting operational inefficiencies.

Balance Sheet

The debt-to-equity ratio increased to 2.30 in 2024, indicating higher leverage and potential financial risk. The equity ratio decreased to 23.27%, suggesting reduced financial stability. Return on equity remains negative due to net losses. The company needs to manage its debt levels to improve financial health.

Cash Flow

Operating cash flow remains negative, though it improved from 2023 to 2024. The free cash flow is also negative, indicating cash outflows exceed inflows. The operating cash flow to net income ratio is positive, suggesting some alignment between cash flow and reported earnings, but overall cash flow management needs improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	320.36M	158.79M	14.75M	9.66M	21.35M
Gross Profit	232.06M	92.19M	14.75M	-25.85M	-9.56M
EBITDA	-156.69M	-311.82M	-484.12M	-295.51M	-155.65M
Net Income	-191.79M	-335.57M	-507.75M	-298.19M	-411.04M
Balance Sheet
Total Assets	1.13B	983.88M	795.58M	1.16B	1.31B
Cash, Cash Equivalents and Short-Term Investments	558.90M	556.55M	377.25M	689.57M	620.44M
Total Debt	635.93M	527.60M	346.06M	295.25M	290.26M
Total Liabilities	916.32M	762.83M	494.63M	419.55M	444.45M
Stockholders Equity	226.36M	228.98M	324.54M	641.72M	670.35M
Cash Flow
Free Cash Flow	-213.39M	-186.09M	-308.63M	-301.70M	-228.64M
Operating Cash Flow	-211.00M	-186.09M	-300.68M	-275.23M	-157.60M
Investing Cash Flow	109.12M	-25.23M	243.11M	-5.70M	-306.69M
Financing Cash Flow	133.17M	351.81M	61.21M	211.49M	281.48M

Qyuns Therapeutics Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2509, the sentiment is Negative. The current price of 28.58 is above the 20-day moving average (MA) of 20.65, above the 50-day MA of 24.92, and above the 200-day MA of 17.74, indicating a neutral trend. The MACD of -0.78 indicates Negative momentum. The RSI at 44.37 is Neutral, neither overbought nor oversold. The STOCH value of 32.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2509.

Qyuns Therapeutics Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	58 Neutral	HK$1.48B	181.90	0.99%	―	9.41%	-32.69%
2197	52 Neutral	HK$2.80B	-2.69	―	―	79.98%	-3.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2509	46 Neutral	HK$4.76B	―	-64.62%	―	―	―
2126	41 Neutral	HK$1.53B	-2.26	-51.56%	―	2.45%	2.58%
6628	41 Neutral	HK$1.17B	―	-34.18%	―	-57.84%	24.58%
2257	40 Neutral	HK$858.24M	―	―	―	―	83.89%

Qyuns Therapeutics Co., Ltd. Class H Corporate Events

Qyuns Therapeutics Announces EGM to Discuss Key Resolutions

Qyuns Therapeutics Co., Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 19, 2025, to discuss and approve key resolutions. These include the renewal of the New Annual Caps for financial years 2026 to 2028 under the QX001S Framework Agreement and proposed amendments to the articles of association. The outcomes of this meeting could significantly impact the company’s operational strategies and governance structure, potentially influencing its market positioning and stakeholder interests.

Qyuns Therapeutics Announces EGM and H Shares Register Closure

Qyuns Therapeutics Co., Ltd., a company incorporated in the People’s Republic of China, has announced the closure of its H shares register from December 16 to December 19, 2025, in preparation for an extraordinary general meeting (EGM) scheduled for December 19, 2025. This meeting will allow shareholders whose names appear on the register by December 15, 2025, to attend and vote, indicating a significant event for stakeholder engagement and corporate governance.

Qyuns Therapeutics’ QX027N Antibody Gains Clinical Trial Approvals

Qyuns Therapeutics Co., Ltd. announced that its long-acting bispecific antibody, QX027N, has received clinical trial approvals for treating asthma and atopic dermatitis, marking a significant milestone in its bispecific antibody pipeline. This development is part of the company’s strategy to advance innovative therapies for respiratory and dermatological diseases, aiming to meet the unmet clinical needs of millions of patients worldwide.

Qyuns Therapeutics Renews Annual Caps for QX001S Framework Agreement

Qyuns Therapeutics Co., Ltd. has announced the renewal of annual caps for the QX001S Framework Agreement with Zhongmei Huadong, a substantial shareholder holding 15.85% of the company’s issued share capital. This renewal pertains to the commercialization of SAILEXIN (QX001S) and involves continuing connected transactions under the Listing Rules. The renewal is subject to independent shareholders’ approval, with Zhongmei Huadong and its associates required to abstain from voting. The company will dispatch a circular to shareholders detailing the new annual caps, recommendations, and proposed amendments to the articles of association.

Qyuns Therapeutics Initiates Share Repurchase to Boost Market Confidence

Qyuns Therapeutics Co., Ltd. announced a voluntary on-market share repurchase, indicating that the board believes the current share price undervalues the company’s worth. The repurchase of 549,800 ordinary shares, valued at approximately HK$11.07 million, aims to reinforce market confidence and enhance investment value, though future repurchases will depend on market conditions.

Qyuns Therapeutics Partners with Roche for Global Development of QX031N

Qyuns Therapeutics Co., Ltd. has entered into a global exclusive license agreement with Roche, granting Roche the rights to develop, manufacture, and commercialize QX031N. This agreement includes an upfront payment of $75 million to Qyuns and potential milestone payments up to $995 million, along with tiered royalties on future sales. The collaboration is expected to enhance Qyuns’ industry positioning by advancing QX031N as a potential ‘First-in-class’ and ‘Best-in-disease’ therapy for respiratory diseases, potentially impacting stakeholders positively with significant financial and market opportunities.

Qyuns Therapeutics Announces Promising Phase III Results for Ankylosing Spondylitis Treatment

Qyuns Therapeutics Co., Ltd. has announced successful Phase III clinical trial results for Crusekitug (QX002N), a treatment for ankylosing spondylitis, presented at the 2025 ACR Annual Meeting. The trial demonstrated significant improvements in clinical symptoms and spinal function, with Crusekitug showing a higher ASAS40 response rate compared to placebo, and favorable safety outcomes. These results position Crusekitug as a promising new treatment option, with the company planning to expedite its registration and market launch.

Qyuns Therapeutics’ Subsidiary Achieves EU QP Certification, Paving Way for Global Expansion

Qyuns Therapeutics Co., Ltd. announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit, meeting the EU GMP standards. This achievement marks a significant milestone in the company’s global expansion strategy, enabling its products to enter the EU market and strengthening its international market presence.